Skip to main content

Advertisement

SpringerLink
Log in

Obiettivi e rischi della terapia del diabete nell’anziano

  • RASSEGNA
  • Published:
L'Endocrinologo Aims and scope

Sommario

Il diabete mellito di tipo 2 (DM2) è una patologia multifattoriale altamente prevalente nella popolazione anziana. Più del 65% della popolazione affetta da DM2 ha infatti un’età maggiore di 65 anni ed esiste uno stretto legame fisiopatologico e clinico tra invecchiamento, DM2 e complicanze vascolari. Ciò impone un’attenta riflessione sui rischi e benefici delle numerose opportunità terapeutiche oggi a disposizione per la cura del DM2. Gli obiettivi terapeutici e le scelte farmacologiche devono essere personalizzati sulla base del grado di complessità del paziente.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Associazione Medici Diabetologi (AMD) (2018) Annali AMD 2018. Idelson-Gnocchi, Napoli

  2. American Diabetes Association AD (2019) 12. Older adults: standards of medical care in diabetes-2019. Diabetes Care 42:S139–S147

    Article  Google Scholar 

  3. International Diabetes Federation (2013) IDF global guideline for managing older people with type 2 diabetes. https://www.idf.org/component/attachments/attachments.html?id=985&task=download. Accessed on 15 November 2018

  4. Schernthaner G, Schernthaner-Reiter MH (2018) Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia 61:1503–1516

    Article  PubMed  PubMed Central  Google Scholar 

  5. Fitzgerald SP, Bean NG (2010) An analysis of the interactions between individual comorbidities and their treatments–implications for guidelines and polypharmacy. J Am Med Dir Assoc 11:475–484

    Article  PubMed  Google Scholar 

  6. Maddaloni E, D’Onofrio L, Pozzilli P (2016) Frailty and geography: should these two factors be added to the ABCDE contemporary guide to diabetes therapy? Diabetes Metab Res Rev 32:169–175

    Article  PubMed  Google Scholar 

  7. Fried LP, Tangen CM, Walston J et al. (2001) Frailty in older adults: evidence for a phenotype. J Gerontol, Ser A, Biol Sci Med Sci 56:M146–156

    Article  CAS  Google Scholar 

  8. Karagiannis T, Paschos P, Paletas K et al. (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, Br Med J 344:e1369–e1369

    Article  CAS  Google Scholar 

  9. Bethel MA, Patel RA, Merrill P et al. (2018) Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113

    Article  PubMed  Google Scholar 

  10. Davies MJ, D’Alessio DA, Fradkin J et al. (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61:2461–2498. 2018

    Article  PubMed  Google Scholar 

  11. Holman RR, Bethel MA, Mentz RJ et al. (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239

    Article  CAS  PubMed  Google Scholar 

  12. Zelniker TA, Wiviott SD, Raz I et al. (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Sperimentale, Università Sapienza di Roma, Roma, Italia

    Ernesto Maddaloni, Ermanno Bellizzi & Raffaella Buzzetti

Authors
  1. Ernesto Maddaloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ermanno Bellizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaella Buzzetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raffaella Buzzetti.

Ethics declarations

Conflitto di interessi

L’autore Ernesto Maddaloni dichiara di aver ricevuto onorari come consulente e/o speaker dalle aziende Merck-Serono, Pikdare, Astrazeneca e Lilly. L’autrice Raffaella Buzzetti dichiara di aver ricevuto onorari come consulente e/o speaker dalle aziende Sanofi, Lilly, Astrazeneca e Abbott. L’autore Ermanno Bellizzi dichiara di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Raffaella Buzzetti.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 28 kB)

(DOC 42 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maddaloni, E., Bellizzi, E. & Buzzetti, R. Obiettivi e rischi della terapia del diabete nell’anziano. L'Endocrinologo 20, 266–271 (2019). https://doi.org/10.1007/s40619-019-00619-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-019-00619-9

Parole chiave

Search

Navigation